246 related articles for article (PubMed ID: 29138210)
1. What Happens After Menopause? (WHAM): protocol for a prospective, multicentre, age-matched cohort trial of risk-reducing bilateral salpingo-oophorectomy in high-risk premenopausal women.
Hickey M; Trainer A; Braat S; Davey MA; Krejany E; Wark J
BMJ Open; 2017 Nov; 7(11):e018758. PubMed ID: 29138210
[TBL] [Abstract][Full Text] [Related]
2. What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
Hickey M; Moss KM; Brand A; Wrede CD; Domchek SM; Meiser B; Mishra GD; Joffe H
Gynecol Oncol; 2021 May; 161(2):527-534. PubMed ID: 33583580
[TBL] [Abstract][Full Text] [Related]
3. What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
Hickey M; Moss KM; Mishra GD; Krejany EO; Domchek SM; Wark JD; Trainer A; Wild RA
Gynecol Oncol; 2021 Jul; 162(1):88-96. PubMed ID: 33972087
[TBL] [Abstract][Full Text] [Related]
4. What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.
Hickey M; Moss KM; Krejany EO; Wrede CD; Domchek SM; Kirk J; Brand A; Trainer A; Mishra GD; Baker FC
Gynecol Oncol; 2021 Aug; 162(2):447-453. PubMed ID: 34116835
[TBL] [Abstract][Full Text] [Related]
5. Loss of bone density and bone strength following premenopausal risk-reducing bilateral salpingo-oophorectomy: a prospective controlled study (WHAM Study).
Jiang H; Robinson DL; Lee PVS; Krejany EO; Yates CJ; Hickey M; Wark JD
Osteoporos Int; 2021 Jan; 32(1):101-112. PubMed ID: 32856124
[TBL] [Abstract][Full Text] [Related]
6. Surgical decision making in premenopausal
Gaba F; Goyal S; Marks D; Chandrasekaran D; Evans O; Robbani S; Tyson C; Legood R; Saridogan E; McCluggage WG; Hanson H; Singh N; Evans DG; Menon U; Manchanda R;
J Med Genet; 2022 Feb; 59(2):122-132. PubMed ID: 33568437
[TBL] [Abstract][Full Text] [Related]
7. Exploring factors that impact uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high-risk women.
Hickey M; Rio I; Trainer A; Marino JL; Wrede CD; Peate M
Menopause; 2020 Jan; 27(1):26-32. PubMed ID: 31613831
[TBL] [Abstract][Full Text] [Related]
8. A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
Islam RM; Davis SR; Bell RJ; Tejada-Berges T; Wrede CD; Domchek SM; Meiser B; Kirk J; Krejany EO; Hickey M
Menopause; 2021 Mar; 28(7):748-755. PubMed ID: 33739311
[TBL] [Abstract][Full Text] [Related]
9. What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?
Hickey M; Rio I; Trainer A; Marino JL; Wrede CD; Peate M
Menopause; 2020 Jan; 27(1):20-25. PubMed ID: 31567874
[TBL] [Abstract][Full Text] [Related]
10. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
Manchanda R; Gaba F; Talaulikar V; Pundir J; Gessler S; Davies M; Menon U;
BJOG; 2022 Jan; 129(1):e16-e34. PubMed ID: 34672090
[TBL] [Abstract][Full Text] [Related]
11. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
Terra L; Beekman MJ; Engelhardt EG; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; Van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Aaronson NK; Mourits MJE; van Leeuwen FE
Am J Obstet Gynecol; 2023 Apr; 228(4):440.e1-440.e20. PubMed ID: 36403862
[TBL] [Abstract][Full Text] [Related]
12. The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis.
Kershaw V; Hickey I; Wyld L; Jha S
Eur J Obstet Gynecol Reprod Biol; 2021 Oct; 265():7-17. PubMed ID: 34416580
[TBL] [Abstract][Full Text] [Related]
13. Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial.
Gaba F; Robbani S; Singh N; McCluggage WG; Wilkinson N; Ganesan R; Bryson G; Rowlands G; Tyson C; Arora R; Saridogan E; Hanson H; Burnell M; Legood R; Evans DG; Menon U; Manchanda R;
Int J Gynecol Cancer; 2021 Feb; 31(2):286-291. PubMed ID: 32907814
[TBL] [Abstract][Full Text] [Related]
14. The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy.
Tucker PE; Bulsara MK; Salfinger SG; Tan JJ; Green H; Cohen PA
Maturitas; 2016 Mar; 85():42-8. PubMed ID: 26857878
[TBL] [Abstract][Full Text] [Related]
15. Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
Stuursma A; van Driel CMG; Wessels NJ; de Bock GH; Mourits MJE
Maturitas; 2018 May; 111():69-76. PubMed ID: 29673834
[TBL] [Abstract][Full Text] [Related]
16. Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations.
Nebgen DR; Domchek SM; Kotsopoulos J; de Hullu JA; Crosbie EJ; Paramanandam VS; Brood-van Zanten MMA; Norquist BM; Guise T; Rozenberg S; Kurian AW; Pederson HJ; Yuksel N; Michaelson-Cohen R; Bober SL; da Silva Filho AL; Johansen N; Guidozzi F; Evans DG; Menon U; Kingsberg SA; Powell CB; Grandi G; Marchetti C; Jacobson M; Brennan DJ; Hickey M
BJOG; 2023 Nov; 130(12):1437-1450. PubMed ID: 37132126
[TBL] [Abstract][Full Text] [Related]
17. What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
Hickey M; Moss KM; Krejany EO; Wrede CD; Brand A; Kirk J; Symecko HL; Domchek SM; Tejada-Berges T; Trainer A; Mishra GD
Gynecol Oncol; 2021 Oct; 163(1):148-154. PubMed ID: 34312002
[TBL] [Abstract][Full Text] [Related]
18. What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
Moss KM; Mishra GD; Krejany EO; Hickey M
Gynecol Oncol; 2022 Oct; 167(1):58-64. PubMed ID: 35933227
[TBL] [Abstract][Full Text] [Related]
19. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy.
Benshushan A; Rojansky N; Chaviv M; Arbel-Alon S; Benmeir A; Imbar T; Brzezinski A
Climacteric; 2009 Oct; 12(5):404-9. PubMed ID: 19479488
[TBL] [Abstract][Full Text] [Related]
20. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
